GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+
The European Commission approved GSK’s Arexvy RSV vaccine for adults 18 and older, expanding access beyond high-risk groups. GSK shares were little changed in early London premarket trading. Investors await Arexvy sales data and the company’s 2026 outlook, due Feb. 4.